ESTRO 36 Abstract Book

S588 ESTRO 36 _______________________________________________________________________________________________

so it needs careful evaluation to measure hypoxic tumor volume at 2-h after administration of FMISO.

study, we aimed to compare the oncologic outcomes and functional larynx-preservation (FLP) rates for advanced clinical T stage (T3-4) hypopharynx and larynx cancer between definitive concurrent chemoradiotherapy (CCRT) and upfront surgery with or without adjuvant therapy. Material and Methods We reviewed the medical records of 148 patients with clinical T3-4 hypopharynx or larynx cancer who were treated between January 2005 and May 2013. Primary treatment was determined in the multidisciplinary team. In the CCRT group (N=63), 7 (11.1%) patients received induction chemotherapy, followed by definitive CCRT. Fifty-five (87.3%) patients were treated with 3- dimensional conformal radiation therapy (RT), and 8 (12.7%) patients with intensity-modulated RT. The median RT dose in the CCRT group was 70 Gy (range, 15.4 to 72 Gy). In the surgery group (N=76), TL was performed in 47 patients (61.8%), partial laryngectomy in 28 patients (36.8%), and partial pharyngectomy only in 1 (1.3%). Fifty- nine (77.6%) patients received adjuvant RT and 5 (6.6%) patients received adjuvant CCRT. Median RT dose in the surgery group was 60 Gy (range, 52 to 70 Gy). Results Median follow-up duration was 46 months (range, 0 to 172 months). In total cohort, the 5-year locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) rates were 68.7%, 56.5%, and 64.1%, respectively. Between the CCRT and surgery group, there was significant difference in LRC rate (CCRT vs. surgery, 57.5% vs. 78.9% at 5 years, p=0.014). The ultimate LRC rate including salvage treatment, however, was not different significantly between the groups (73.2 vs. 81.7% at 5 years, p=0.209). There was no significant difference in PFS (p=0.175), and OS rates (p=0.965) between the groups. On the multivariate analysis, treatment modality was not independent factor for oncologic outcomes.

EP-1069 Survival-weight health profile in nasopharyngeal cancer patients C.H. Lai 1 , W.C. Chen 1 , M.F. Chen 1 1 Chang-Gung Memorial Hospital- Chiayi branch, Radiation Oncology, Chiayi Conuty, Taiwan

Purpose or Objective This

study was designed to estimate the life expectancy (LE), quality-adjusted life expectancy (QALE) and survival- weight psychometric scores (SWPS) in nasopharyngeal

cancer (NPC) patients. Material and Methods

A sample of 875 non-metastatic NPC patients diagnosed between January 1, 2009 and June 30, 2013 was collected from the cancer registry database in four branch hospitals of our hospital system for estimation of lifetime survival function. All 875 patients were followed up until death or censored on December 31, 2015. To obtain the utility and psychometric score for estimation of LE, QALE and SWPS, eighty-seven patients were measured with the Taiwanese version of the EuroQol instrument (EQ-5D) and the Taiwan Chinese versions of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and QLQ-H&N35 between October 1, 2013 and March 31, 2016. The LE of NPC patients was obtained using linear extrapolation of a logit- transformed curve and was adjusted by the corresponding QOL function to calculate the QALE and SWPS. Results The mean age at diagnosis of the 875 non-metastatic NPC patients was 50.7 years. The median duration from the beginning of radiotherapy to the date of completing questionnaires was 6.5 months (range, 0-154.9 months). The average LE and QALE were estimated to be 15.7 years and 14.5 quality-adjusted life years (QALYs) for NPC patients and 29.5 years and 29.5 QALYs for the reference population, respectively. On average, the lifelong duration of pain and painkiller use were 5.7 years and 1.8 years. The lifelong duration of any impairment of swallowing, smell and taste were 14.6 years, 8.5 years and 6.9 years, respectively. The life long duration of dry mouth was 13.3 years. Furthermore, the lifelong duration of tube-feeding was only 1.5 months. Conclusion This study offers more understandable information than the 5 year survival outcomes when communicating with patients or the general population regarding cancer risk and the impact of treatments on the quality of life. In the future, evaluating the robustness of comparative assessments for the outcome of NPC patients undergoing different treatment protocols will be possible. EP-1070 Concurrent chemoradiation versus upfront surgery for clinical T3-4 hypopharynx and larynx cancer G.S. Yoo 1 , D. Oh 1 , J.M. Noh 1 , Y.C. Ahn 1 , C.H. Baek 2 , Y.I. Son 2 , H.S. Jeong 2 , J.M. Sun 3 , M.J. Ahn 3 , K. Park 3 1 Samsung Medical Center, Department of Radiation Oncology, Seoul, Korea Republic of 2 Samsung Medical Center, Department of Otorhinolaryngology-Head and Neck Surgery, Seoul, Korea Republic of 3 Samsung Medical Center, Department of Medicine- Division of Hematology-Oncology, Seoul, Korea Republic of Purpose or Objective The optimal treatment regimen for advanced T stage hypopharynx and larynx cancer is controversial. In this

The 5-year FLP rate was higher significantly in CCRT group (75.4% vs. 35.5%, p<0.001). The laryngoesophageal dysfunction-free survival rate in CCRT group was 56.9%. On the multivariate analysis, treatment modality was independent factor in FLP with hazard ratio of CCRT group as 0.261 (95% confidential interval with 0.139-0.488, p<0.001). Conclusion Under the multidisciplinary approach, there were no significant differences in oncologic outcomes between the CCRT and surgery groups, while CCRT gave more opportunity to preserve the laryngeal function.